Alumis, Inc. (ALMS)
23.96
+0.94
(+4.06%)
USD |
NASDAQ |
Aug 25, 16:00
23.96
0.00 (0.00%)
After-Hours: 17:40
Alumis Shareholders Equity (Quarterly) : 452.16M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 452.16M |
| March 31, 2026 | 567.02M |
| December 31, 2025 | 301.30M |
| September 30, 2025 | 384.77M |
| June 30, 2025 | 485.33M |
| March 31, 2025 | 168.31M |
| Date | Value |
|---|---|
| December 31, 2024 | 260.10M |
| September 30, 2024 | 348.39M |
| June 30, 2024 | 200.48M |
| March 31, 2024 | 109.65M |
| December 31, 2023 | 36.11M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 705.78M |
| Aclaris Therapeutics, Inc. | 124.58M |
| Crinetics Pharmaceuticals, Inc. | 1.192B |
| Tarsus Pharmaceuticals, Inc. | 346.73M |
| Structure Therapeutics, Inc. | 1.354B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 560.62M |
| Total Liabilities (Quarterly) | 108.46M |
| Debt to Equity Ratio | 0.0806 |
| Current Ratio | 6.744 |
| Net Debt Paydown Yield | -0.03% |